Journal of Carcinogenesis & Mutagenesis

Oncogenes and Signal Transduction Pathways in Cancer

Serena Vaelor^* Department of Molecular Oncology, Institute for Cancer Genomics and Therapeutics Edinburgh, United Kingdom
^*Correspondence: Serena Vaelor, Department of Molecular Oncology, Institute for Cancer Genomics and Therapeutics Edinburgh, United Kingdom, Email:

Received: 27-Apr-2026, Manuscript No. JCM-26-31973; Editor assigned: 29-Apr-2026, Pre QC No. JCM-26-31973 (PQ); Reviewed: 13-May-2026, QC No. JCM-26-31973; Revised: 20-May-2026, Manuscript No. JCM-26-31973 (R); Published: 27-May-2026, DOI: 10.35248/2157-2518.26.17.508

Description

Oncogenes are mutated or abnormally expressed forms of normal cellular genes known as proto-oncogenes that play a central role in the initiation and progression of cancer. Proto-oncogenes normally regulate essential cellular processes, including growth, differentiation, proliferation and survival. Under physiological conditions, these genes contribute to tissue development and maintenance by responding appropriately to extracellular signals. However, when proto-oncogenes undergo genetic alterations such as point mutations, gene amplification, chromosomal translocations, or abnormal regulation of gene expression, they become oncogenes capable of promoting uncontrolled cellular proliferation and malignant transformation. The discovery of oncogenes has significantly advanced the understanding of molecular carcinogenesis and has opened new opportunities for targeted cancer therapies and personalized medicine.

The concept of oncogenes emerged from studies of tumor-causing viruses, which revealed that viral genomes contained genes capable of transforming normal cells into cancerous cells. Subsequent research demonstrated that similar genes are naturally present within the human genome as proto-oncogenes. Activation of these genes through genetic or epigenetic alterations converts them into oncogenes that continuously stimulate signaling pathways involved in cell growth and survival. Unlike tumor suppressor genes, which generally require the loss of both functional alleles to contribute to cancer development, activation of a single oncogenic allele is often sufficient to initiate abnormal cellular behavior. This dominant effect makes oncogenes critical drivers of many human malignancies.

Several molecular mechanisms are responsible for oncogene activation. Point mutations can produce proteins with constitutive activity that remain permanently switched on, continuously transmitting growth-promoting signals independent of external stimuli. Gene amplification results in multiple copies of an oncogene, leading to excessive protein production and enhanced proliferative signaling. Chromosomal translocations may place proto-oncogenes under the control of highly active promoters or generate novel fusion proteins with oncogenic properties. Epigenetic modifications, including altered DeoxyribonucleicAcid (DNA) methylation and histone modifications, may also increase oncogene expression without changing the underlying DNA sequence. These diverse mechanisms illustrate the complexity of oncogene regulation and highlight multiple pathways through which malignant transformation can occur.

Numerous oncogenes have been identified in human cancers, each contributing to specific aspects of tumor biology. The gene family represents one of the most frequently mutated and oncogene groups and regulates signaling pathways involved in cell proliferation and differentiation. Mutations in genes result in persistent activation of downstream signaling cascades that drive uncontrolled growth in pancreatic, colorectal and lung cancers. Myelocytomatosis (MYC) is another well characterized oncogene that functions as a transcription factor regulating genes involved in c e l l c ycle p rogression, m e t a b olism and protein synthesis. Over e x p ression o f MYC h as b e e n o b served in many hematological a n d solid m alignancies. H uman E pidermal Growth Factor R e c eptor 2 (HER2) amplification is commonly associated with aggressive breast and gastric cancers, while abnormal activation of Breakpoint Cluster Region-Abelson (BCR-ABL) resulting from chromosomal translocation plays a fundamental role in chronic myeloid leukemia. These examples demonstrate that different oncogenes contribute to cancer development through distinct molecular mechanisms.

Conclusion

oncogenes are fundamental regulators of cancer development because their abnormal activation disrupts the normal balance between cellular proliferation, differentiation and apoptosis. Their diverse mechanisms of activation and broad influence on multiple cancer-related pathways make them central to the study of carcinogenesis. Advances in molecular diagnostics and targeted therapeutics have greatly improved the ability to detect and inhibit oncogenic signaling, leading to more personalized and effective cancer treatment strategies.